CRVS logo

CRVS
Corvus Pharmaceuticals Inc

6,737
Mkt Cap
$1.15B
Volume
3.49M
52W High
$26.95
52W Low
$3.38
PE Ratio
-23.40
CRVS Fundamentals
Price
$12.31
Prev Close
$13.66
Open
$13.47
50D MA
$15.16
Beta
1.44
Avg. Volume
1.23M
EPS (Annual)
-$0.5372
P/B
4.30
Rev/Employee
$0.00
$552.22
Loading...
Loading...
News
all
press releases
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are presently covering the stock...
MarketBeat·15d ago
News Placeholder
More News
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3% - Here's Why
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 8.3% - What's Next...
MarketBeat·17d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen raised shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·21d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2% - Here's Why
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 10.2% - What's Next...
MarketBeat·23d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5% - What's Next?
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 9.5% Higher - Here's What Happened...
MarketBeat·25d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group
The Goldman Sachs Group raised shares of Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Friday...
MarketBeat·28d ago
News Placeholder
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside
Goldman Sachs initiated coverage of Corvus with a ‘Buy’ rating and $40 price target, according to The Fly.
Stocktwits·29d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - What's Next...
MarketBeat·29d ago
News Placeholder
This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according to Goldman Sachs...
CNBC: Top News·29d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 4.3% - Should You Sell?
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 4.3% - Here's What Happened...
MarketBeat·1mo ago
<
1
2
...
>

Latest CRVS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.